Hereditary Breast and Ovarian Cancer Syndrome Clinical Trial
Official title:
Cohort Study on Characters and Distribution of Inherited Susceptible Genes Among Epithelial Ovarian Cancer Patients and Their Relatives in the North of China
NCT number | NCT03015376 |
Other study ID # | EOC-GENE |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | January 2017 |
Est. completion date | January 2019 |
Purpose: To investigate the prevalence of the germline mutations in the BRCA 1/2 and mismatch
repair genes in patients with epithelial ovarian cancer (EOC) and their relatives, and
related somatic mutations in tumor tissues in the northern part of china.
Patients and methods: A multicenter prospective study will be hold in the northern part of
china form 2017. About 1000 female patients with epithelial ovarian cancer and their
ralatives will be tested for germline mutations in the BRCA 1/2 and mismatch repair genes and
related somatic mutations in tumor tissues, regardless of the family history.
Study type: Observational Official title: Prevalence study of germline mutations in
susceptibility ovarian cancer genes in patients with epithelial ovarian cancer and somatic
mutations in their tumor tissures in the northern part of china.
Enrollment: 1000
Status | Recruiting |
Enrollment | 1000 |
Est. completion date | January 2019 |
Est. primary completion date | January 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: 1. epithelial ovarian cancer and their relatves 2. living in the north of Huaihe River in China 3. being Han Chinese Exclusion Criteria: 1. non-epithelial ovarian cancer 2. without specific pathological diagnosis 3. non-Han Chinese |
Country | Name | City | State |
---|---|---|---|
China | Lei Li | Beijing | Beijing |
China | Peking Union Medical College Hospital | Beijing | Beijing |
Lead Sponsor | Collaborator |
---|---|
Peking Union Medical College Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | herited gene mutations susceptible to epithelial ovarian cancer in patients and their relatives | two years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00535119 -
Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer
|
Phase 1 | |
Recruiting |
NCT03294343 -
Risk-Reducing Surgeries for Hereditary Ovarian Cancer
|
N/A | |
Completed |
NCT02956681 -
Statewide Communication to Reach Diverse Low Income Women
|
N/A | |
Completed |
NCT00305695 -
Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries
|
Phase 2 | |
Active, not recruiting |
NCT03832985 -
Pediatric Reporting of Adult-Onset Genomic Results
|
Early Phase 1 | |
Active, not recruiting |
NCT02760849 -
Surgery in Preventing Ovarian Cancer in Patients With Genetic Mutations
|
N/A | |
Recruiting |
NCT02653105 -
Women at Risk of Breast Cancer and OLFM4
|
N/A | |
Completed |
NCT01367639 -
Trial of Inquiry Based Stress Reduction (IBSR) Program for BRCA1/2 Mutation Carriers
|
Phase 2 | |
Completed |
NCT02562170 -
Protexa® Versus TiLoopBra® in Immediate Breast Reconstruction- A Pilot Study
|
Phase 4 | |
Recruiting |
NCT03162276 -
Trial of Inquiry Based Stress Reduction (IBSR) Program for BRCA1/2 Mutation Carriers
|
Phase 3 | |
Not yet recruiting |
NCT01445275 -
Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199
|
N/A | |
Enrolling by invitation |
NCT04197856 -
Direct Information to At-risk Relatives
|
N/A | |
Completed |
NCT03784859 -
Tissue Expansion in Breast Reconstruction Without Drains
|
||
Completed |
NCT04544501 -
Enhance the Use of Genetic Counseling and Testing in Latinas
|
N/A | |
Completed |
NCT00609505 -
Telemedicine vs. Face-to-Face Cancer Genetic Counseling
|
N/A | |
Terminated |
NCT02705924 -
Impact of a Psychoeducational Intervention on Expectations and Coping in Young Women Exposed to a High HBOC Risk
|
N/A | |
Completed |
NCT01333748 -
Search Allelic Imbalance of Expression of BRCA Genes in Hereditary Risk of Breast and/or Ovarian Cancer
|
Phase 2 | |
Completed |
NCT00892736 -
Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy
|
Phase 1 | |
Recruiting |
NCT05677048 -
Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention
|
N/A |